GCLC

Across TCGA pan-cancer cohorts, GCLC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GCLC data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GCLC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GCLC expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where GCLC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.956	0.638	.002	63	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	41	view →
LSCC	DFS	Median	II,III,IV	1.000	0.837	.006	4	view →
HNSC	OS	Tertile	All	0.627	0.836	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GCLC–CCRCC (OS)

Open the CCRCC breakdown →